ReviewVaccines2023
Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Equine Sarcoid: From BPV-Driven Oncogenesis to Host-Sustained Tumor Persistence.Pathogens (Basel, Switzerland) · 2026Review
- Electrochemotherapy Following Surgical Cytoreduction for the Treatment of Recurrent Equine Sarcoids: A Retrospective Study of 23 Lesions.Veterinary sciences · 2026Article
- Equine models in translational medicine: A comparative approach to human health.Animal models and experimental medicine · 2026Review
- Cancer Across Domestic Animals: A Descriptive Review from the Veterinarian's Perspective.Veterinary sciences · 2026Review
- Targeting Toll-like Receptor 2: synthetic diacylated lipopeptides polarize equine macrophages towards a pro-inflammatory phenotype.Frontiers in immunology · 2026Article
- Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas.Equine veterinary journal · 2026Article
- Proof of concept for low dose and delayed release of tigilanol tiglate in the treatment of equine sarcoids.Frontiers in veterinary science · 2026Article
- BCG Immunotherapy in Equine Sarcoid Treatment: Mechanisms, Clinical Efficacy, and Challenges in Veterinary Oncology.Viruses · 2025Review
- Genetic susceptibility to sarcoid in Arabian horses: associations with MHC class II and compound MHC class I/KLRA genotypes.Veterinary research communications · 2025Article
- Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024).Veterinary sciences · 2025Review
- Outcomes following autologous tumor tissue implantation with or without concurrent antineoplastic therapies in the treatment of sarcoids in 50 equids.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Horses and other equid species are frequently affected by bovine papillomavirus type 1 and/or 2 (BPV1, BPV2)-induced skin tumors termed sarcoids. Although sarcoids do not metastasize, they constitute a serious health problem due to their BPV1/2-mediated resistance to treatment and propensity to recrudesce in a more severe, multiple form following accidental or iatrogenic trauma. This review provides an overview on BPV1/2 infection and associated immune escape in the equid host and presents early and recent immunotherapeutic approaches in sarcoid management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.